Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000664446 | SCV000788410 | uncertain significance | 3-Methylglutaconic aciduria type 3 | 2017-04-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002485516 | SCV002783702 | uncertain significance | 3-Methylglutaconic aciduria type 3; Optic atrophy 3 | 2021-12-20 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002532031 | SCV003687287 | uncertain significance | Inborn genetic diseases | 2022-01-19 | criteria provided, single submitter | clinical testing | The c.445delC (p.L149Wfs*67) alteration, located in exon 2 (coding exon 2) of the OPA3 gene, consists of a deletion of one nucleotide at position 445, causing a translational frameshift with a predicted alternate stop codon after 67 amino acids. Frameshift alterations are typically deleterious in nature (Richards, 2015). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |